Mainz Biomed (MYNZ) - צמיחה צפויה ברווח למניה לשנה הבאה

Mainz Biomed N.V. is developing non-invasive colorectal cancer diagnostics, diversifying across US and European markets. The forward EPS forecast for the coming year is derived from the GURU.Markets chart, where 98.70 represents the current metric. This confirms the company's ESG status by reducing bio-waste and strictly adhering to medical regulations regarding chemical disposal in laboratories.
MYNZ (Mainz Biomed NV): פילוחים אנליטיים ודוחות לפי אינדיקטורים

The positive trend in the forward net income growth rate reflects market confidence in the commercialization of Mainz Biomed N.V. (MYNZ) non-invasive tests in Europe and the US. This indicator measures the percentage change in expected earnings per share (EPS) for the following year, allowing investors to assess the fundamental resilience of the business and adjust their entry strategy for the asset in a timely manner.